Slovin S, et al. - The authors aimed to determine seizure incidence in patients with seizure risk factors who were receiving enzalutamide for metastatic castration-resistant prostate cancer (mCRPC). They observed that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors. In addition to the previously established efficacy of enzalutamide, the presented risk profile suggested that enzalutamide could benefit patients with a history of seizures or other predisposing factors, but each patient should be closely monitored for the duration of treatment.